Y-90 radioembolization extends life in liver cancer

Share this article:

Higher doses of yttrium-90 (Y-90) than previously used in intra-arterial radioembolization to treat persons with liver tumors provide results when chemotherapies have failed, according to study findings presented at the recent annual scientific meeting of the Society of Interventional Radiology, held in Chicago.

Although radioembolization is a palliative rather than a curative technique, several subgroups included in a 4-year, 151-person study by Riad Salem, MD, MBA, and colleagues showed high rates of progression-free survival with fewer side effects. In one case, a 60-year-old woman with advanced liver cancer that had metastasized from neuroendocrine tumors had lesions that were progressing as she continued to undergo standard chemotherapy treatments. At the higher dose of Y-90 used in the trial, the lesion progression reversed and the tumors shrank with no adverse events.

This outpatient treatment combines the radioactive isotope Y-90 into microspheres—beads approximately the width of five blood cells. The microspheres deliver radiation directly to a tumor. “We knew that this unique interventional radiology treatment … was one of the best ways to give patients a treatment that doesn't harm healthy cells,” affirmed Dr. Salem, the director of interventional oncology in the radiology department at Northwestern University, in a statement describing his group's findings. “Now we know that patients can actually tolerate much higher doses of radiation than previously thought, which provides results in patients progressing on standard chemotherapy.”

The microspheres are injected through a catheter into the hepatic artery. The beads lodge within tumor vessels and radiate the cancerous cells. This “internal radiation” technique permits the use of a higher, local dose of radiation that does not endanger healthy tissue.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.